From the Division of Trauma, Emergency Surgery and Surgical Critical Care (O.A., A.M., L.N., K.L., K.A.B., M.E.M., C.K., A.G., M.A.C., L.R.M., H.M., B.B.-K., J.P., J.F., N.S., A.M., C.P., P.F., D.K., J.L., G.C.V., H.M.A.K.), and Division of Pulmonary Critical Care (M.R.F.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
J Trauma Acute Care Surg. 2021 May 1;90(5):880-890. doi: 10.1097/TA.0000000000003085.
We sought to describe characteristics, multisystem outcomes, and predictors of mortality of the critically ill COVID-19 patients in the largest hospital in Massachusetts.
This is a prospective cohort study. All patients admitted to the intensive care unit (ICU) with reverse-transcriptase-polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 infection between March 14, 2020, and April 28, 2020, were included; hospital and multisystem outcomes were evaluated. Data were collected from electronic records. Acute respiratory distress syndrome (ARDS) was defined as PaO2/FiO2 ratio of ≤300 during admission and bilateral radiographic pulmonary opacities. Multivariable logistic regression analyses adjusting for available confounders were performed to identify predictors of mortality.
A total of 235 patients were included. The median (interquartile range [IQR]) Sequential Organ Failure Assessment score was 5 (3-8), and the median (IQR) PaO2/FiO2 was 208 (146-300) with 86.4% of patients meeting criteria for ARDS. The median (IQR) follow-up was 92 (86-99) days, and the median ICU length of stay was 16 (8-25) days; 62.1% of patients were proned, 49.8% required neuromuscular blockade, and 3.4% required extracorporeal membrane oxygenation. The most common complications were shock (88.9%), acute kidney injury (AKI) (69.8%), secondary bacterial pneumonia (70.6%), and pressure ulcers (51.1%). As of July 8, 2020, 175 patients (74.5%) were discharged alive (61.7% to skilled nursing or rehabilitation facility), 58 (24.7%) died in the hospital, and only 2 patients were still hospitalized, but out of the ICU. Age (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.04-1.12), higher median Sequential Organ Failure Assessment score at ICU admission (OR, 1.24; 95% CI, 1.06-1.43), elevated creatine kinase of ≥1,000 U/L at hospital admission (OR, 6.64; 95% CI, 1.51-29.17), and severe ARDS (OR, 5.24; 95% CI, 1.18-23.29) independently predicted hospital mortality.Comorbidities, steroids, and hydroxychloroquine treatment did not predict mortality.
We present here the outcomes of critically ill patients with COVID-19. Age, acuity of disease, and severe ARDS predicted mortality rather than comorbidities.
Prognostic, level III.
我们旨在描述马萨诸塞州最大医院中 COVID-19 危重症患者的特征、多系统结局和死亡预测因素。
这是一项前瞻性队列研究。纳入 2020 年 3 月 14 日至 4 月 28 日期间因经逆转录酶聚合酶链反应确诊的严重急性呼吸综合征冠状病毒 2 感染而入住重症监护病房(ICU)的所有患者;评估了医院和多系统结局。数据从电子病历中收集。急性呼吸窘迫综合征(ARDS)定义为入院时 PaO2/FiO2 比值≤300 和双侧放射性肺混浊。通过调整可用混杂因素的多变量逻辑回归分析,确定死亡的预测因素。
共纳入 235 例患者。序贯器官衰竭评估评分的中位数(四分位距[IQR])为 5(3-8),PaO2/FiO2 的中位数(IQR)为 208(146-300),86.4%的患者符合 ARDS 标准。中位(IQR)随访时间为 92(86-99)天,中位 ICU 住院时间为 16(8-25)天;62.1%的患者被俯卧位,49.8%需要神经肌肉阻滞剂,3.4%需要体外膜氧合。最常见的并发症是休克(88.9%)、急性肾损伤(AKI)(69.8%)、继发性细菌性肺炎(70.6%)和压疮(51.1%)。截至 2020 年 7 月 8 日,175 例患者(74.5%)存活出院(61.7%至熟练护理或康复设施),58 例(24.7%)在医院死亡,仅 2 例患者仍住院,但已离开 ICU。年龄(比值比[OR],1.08;95%置信区间[CI],1.04-1.12)、ICU 入院时较高的中位序贯器官衰竭评估评分(OR,1.24;95%CI,1.06-1.43)、入院时肌酸激酶≥1000U/L(OR,6.64;95%CI,1.51-29.17)和严重 ARDS(OR,5.24;95%CI,1.18-23.29)独立预测医院死亡率。合并症、类固醇和羟氯喹治疗并不能预测死亡率。
我们在此介绍 COVID-19 危重症患者的结局。年龄、疾病严重程度和严重 ARDS 预测死亡率,而不是合并症。
预后,III 级。